Lantheus Holdings, Inc. (LNTH)

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

• Informe anual (10-K)

  Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.

  Presentado el 2026-02-26

  Ver documento

• Informe trimestral (10-Q)

  Una actualización del desempeño financiero de los últimos tres meses.

  Presentado el 2026-08-06

  Ver documento

• Informe de hecho relevante (8-K)

  Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.

  Presentado el 2026-09-21

  Ver documento

• 7/27/2026POSITIVE
  Curium Is Said to Near About $7 Billion Acquisition of Lantheus

  Lantheus Holdings Inc. is reportedly in advanced acquisition talks with Curium, with the deal potentially valued at around $7 billion. This news suggests a significant premium for Lantheus shareholders, as acquisition offers typically exceed current market valuations. The potential transaction highlights the strategic value of Lantheus's radiopharmaceutical assets and could lead to a substantial uplift in its stock price if the deal materializes. Investors will be closely watching for official announcements and deal terms.

• 5/22/2026POSITIVE
  Lantheus Weighs Potential $7 Billion Sale Following Offer From Curium

  Lantheus Holdings Inc. is reportedly considering a sale following a takeover bid from Curium, which values the radiopharmaceutical company at approximately $7 billion. This potential acquisition signals strong interest in Lantheus's market position and assets. For shareholders, this news suggests a significant premium could be realized if a deal is finalized, potentially offering a lucrative exit. The valuation indicates robust investor confidence in the company's future prospects and its role within the growing radiopharma sector.

• 3/9/2026POSITIVE
  Why Lantheus Holdings Stock Popped by Almost 12% Last Month

  Lantheus Holdings Inc. saw its stock price surge by nearly 12% in the past month, a significant move driven by investor enthusiasm over the medical device specialist's robust fourth-quarter financial results. While specific figures were not detailed in the provided snippet, the market's positive reaction indicates that the company likely exceeded earnings expectations or demonstrated strong revenue growth and positive future outlook. This performance suggests effective operational execution and potentially successful product launches or market penetration, making LNTH an attractive prospect for investors seeking growth in the healthcare sector.

• 2/26/2026NEUTRAL
  Lantheus (LNTH) Q4 2025 Earnings Call Transcript

  Lantheus (LNTH) is currently under investor scrutiny as the market awaits the release of its Q4 2025 earnings call transcript. While specific details from the discussion are not yet available, this event is a critical juncture for understanding the company's financial performance and future outlook. Analysts and shareholders closely monitor these calls to assess revenue growth, profitability, and development strategies, particularly within the diagnostic and therapeutic products sector. The immediate lack of information from the transcript keeps the stock in a holding pattern, with the market weighing potential implications once the data becomes public. Market reaction will heavily depend on management's guidance, product pipeline updates, and competitive challenges.